<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988026</url>
  </required_header>
  <id_info>
    <org_study_id>MXMIN-001</org_study_id>
    <nct_id>NCT00988026</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Comparison of Minocycline Microgranules Versus Lymecycline in the Treatment of Mild to Moderate Acne</brief_title>
  <acronym>MXMIN-001</acronym>
  <official_title>Safety and Efficacy Comparison of Minocycline Microgranules vs Lymecycline in the Treatment of Mild to Moderate Acne. Randomized, Double Blind, Parallel and Prospective Clinical Trial for 8 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Darier</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Darier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial to compare the benefits and possible adverse events of two
      antibiotic treatments for mild to moderate acne. It is expected that minocycline
      microgranules will be more effective than lymecycline with a better adverse events profile.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of inflammatory and non-inflammatory acne lesions</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of local and systemic adverse events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Mild to Moderate Acne</condition>
  <arm_group>
    <arm_group_label>Minocycline 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymecycline 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: Lymecycline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline vs Lymecycline</intervention_name>
    <description>Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.</description>
    <arm_group_label>Minocycline 100 mg</arm_group_label>
    <arm_group_label>Lymecycline 300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both gender

          -  14 to 30 years old

          -  Mild to moderate acne

          -  Face localization

          -  At least 20 non-inflammatory lesions OR

          -  At least 15 inflammatory lesions OR

          -  At least 30 total lesions AND

          -  Less than 5 nodular lesions

        Exclusion Criteria:

          -  Patients younger than 14 or older than 30 years old

          -  Less than 20 non-inflammatory lesions OR

          -  Less than 15 inflammatory lesions OR

          -  Less than 30 total lesions

          -  Patients with severe acne

          -  More than 5 nodular lesions OR

          -  More than 50 inflammatory lesions OR

          -  More than 125 total lesions

          -  Pregnant women

          -  Lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luis Leobardo Velázquez-Arenas, MD</last_name>
    <phone>(5281)83481465</phone>
    <email>leovel2002@yahoo.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jorge Ocampo-Candiani, MD</last_name>
    <phone>(5281)83481465</phone>
    <email>jocampo2000@yahoo.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Servicio de Dermatología. Hospital &quot; Dr. José Eleuterio González&quot; de la Universidad Autónoma de Nuevo León</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Ojeda-Martínez, RN</last_name>
      <phone>(5281)83481465</phone>
      <email>blanca_ojeda21@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <last_update_submitted>September 30, 2009</last_update_submitted>
  <last_update_submitted_qc>September 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Luis Leobardo Velázquez-Arenas</name_title>
    <organization>Hospital &quot;Dr. José Eleuterio González&quot; de la Universidad Autónoma de Nuevo Léon</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Lymecycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

